Cow’s Milk Protein Allergy (CMPA) is often the first allergy that appears during early childhood and affects approximately 2-3 percent of the population in developed countries.
We have completed a Phase 1/2 trial to study the safety and efficacy of Viaskin Milk in pediatric and adolescent patients.
Clinical Trials (IgE-mediated Cow’s Milk Allergy)
MILES (Viaskin Milk Efficacy and Safety)
Pilot Clinical Trial of Epicutaneous Immunotherapy in Cow’s Milk Allergy with Assistance Publique Hopitaux de Paris (AP-HP)
Clinical Trials (Non-IgE-mediated Cow’s Milk Allergy Diagnosis)
* Viaskin Milk is an investigational product and has not been approved for any use in any country.